 Uzbekistan today offers one of the most dynamic and strategically positioned pharmaceutical markets in Eurasia. What differentiates Uzbekistan from many other emerging markets is the combination of strong political commitment, rapid regulatory modernization, large-scale industrial infrastructure development, and direct government support for investors, says Abdulla Azizov, Chairman of the Medical and Pharmaceutical Industry Development Agency and the First Deputy Minister of Health of the Republic of Uzbekistan in an exclusive interview with Shardul Nautiyal.
Abdulla Azizov further shares, “Over the past several years, the President of the Republic of Uzbekistan has prioritized pharmaceutical industry development as a strategic national objective. This has resulted in substantial reforms aimed at localization, technology transfer, Good Manufacturing Practices (GMP) alignment, and export-oriented manufacturing. Investors benefit from a rapidly growing domestic market, competitive production costs, preferential conditions within special industrial zones, and direct access to the broader Central Asian and CIS markets.”
He further adds that Uzbekistan is not simply focused on becoming a manufacturing destination. Our goal is to build a vertically integrated pharmaceutical and biotechnology ecosystem encompassing production, R&D, education, clinical research, and innovation. This long-term vision, combined with Uzbekistan’s strategic geographic location between Europe and Asia, creates a highly attractive platform for international pharmaceutical companies seeking regional expansion.
Uzbekistan has seen a rapid influx of foreign investment into its pharmaceutical sector, with over USD 980 million invested in Bio Pharma City alone and strong participation from global players. The development of Bio Pharma City as a large-scale integrated ecosystem combining manufacturing, education, and R&D is a flagship initiative.
Excerpts -
What differentiates Bio Pharma City from other pharmaceutical clusters globally, and what types of investors or technologies are you prioritizing for this platform?
Bio Pharma City represents a new-generation pharmaceutical and biotechnology cluster designed as a fully integrated ecosystem rather than a traditional industrial park.
What makes Bio Pharma City unique is the combination of advanced GMP-compliant manufacturing infrastructure with biotechnology research centers, clinical trial capabilities, educational institutions, and innovation facilities within a single coordinated platform. The cluster includes facilities such as the Genome and Biotechnology Research Center, Clinical and Preclinical Research Center, Pharmaceutical Technical University, R&D laboratories, state agencies & regulatory body, and modern quality-control infrastructure.
Another key differentiator is the level of institutional support provided by the Government of Uzbekistan. Investors entering Bio Pharma City receive not only infrastructure, but also regulatory facilitation, localization support, investment assistance, and access to highly prioritized strategic projects.
Today, we are particularly prioritizing investments and technologies related to biotechnology, biologics manufacturing, blood products, biosimilars, innovative drug development, medical technologies, and contract manufacturing partnerships. We are also highly interested in attracting companies specializing in technology transfer and R&D collaboration. Uzbekistan is increasingly emphasizing biotechnology, including vaccines, blood products, and innovative drug development.
How central is biotechnology to Uzbekistan’s long-term pharmaceutical strategy, and which specific subsectors (e.g., biologics, cell therapy, vaccines) are considered priority areas for development?
Biotechnology is becoming one of the central pillars of Uzbekistan’s long-term pharmaceutical strategy. Globally, the pharmaceutical industry is rapidly transitioning toward biologics, personalized medicine, advanced therapies, and innovative biotechnology-driven solutions. Uzbekistan recognizes this transformation and aims to position itself as a regional biotechnology hub in Central Asia.
Priority subsectors currently include biosimilars development and manufacturing, plasma-derived and blood products, monoclonal antibodies, biotechnology-based diagnostics, regenerative medicine, and advanced biopharmaceutical production technologies.
In addition, we are actively exploring partnerships related to genomic research, cell technologies, and innovative therapeutic platforms. The development of biotechnology infrastructure within Bio Pharma City reflects our intention to move beyond traditional generic manufacturing toward higher-value pharmaceutical innovation.
There are ongoing discussions with international partners to establish R&D centers and relocate research projects to Uzbekistan.
What concrete steps is the Agency taking to build a competitive R&D ecosystem, and how do you plan to attract both multinational and local innovation-driven companies?
The Agency is taking a comprehensive approach toward building a sustainable pharmaceutical R&D ecosystem.
First, significant investments are being directed toward the development of scientific and innovation infrastructure, including research laboratories, biotechnology centers, and clinical research facilities. Second, we are strengthening cooperation with international universities, pharmaceutical companies, and research institutions to facilitate knowledge transfer and joint scientific projects.
We are also working to create favourable conditions for multinational companies willing to establish R&D activities in Uzbekistan, including regulatory facilitation, localization incentives, tax benefits and integration with manufacturing platforms within Bio Pharma City.
An equally important objective is supporting local innovation-driven companies and startups. We believe long-term competitiveness requires the parallel development of domestic scientific capacity alongside international cooperation.
Clinical research is another strategic area. Uzbekistan has significant potential to become an attractive destination for clinical trials due to its population demographics, growing healthcare infrastructure, and improving regulatory environment. Uzbekistan is investing in pharmaceutical education and workforce development to sustain industry growth.
How do you assess the current readiness of Uzbekistan’s scientific and technical workforce to support advanced pharmaceutical manufacturing and research, particularly in biotechnology?
Uzbekistan understands that infrastructure alone is not sufficient for building a globally competitive pharmaceutical industry. Human capital development is equally critical.
Today, the country is investing heavily in pharmaceutical education, scientific training, and workforce development. The establishment of the Pharmaceutical Technical University and specialized biotechnology education programs is intended to prepare a new generation of professionals capable of supporting advanced pharmaceutical manufacturing and research.
At the same time, we recognize that biotechnology and innovative pharmaceutical production require highly specialized expertise. Therefore, international cooperation in education and training remains a major priority. We are actively pursuing partnerships involving academic exchange, joint research programs, technical internships, and industry-led professional development initiatives.
Our objective is to gradually build a workforce capable of supporting not only generic production, but also advanced biotechnology, R&D, and innovation-driven pharmaceutical activities.
The government aims to significantly increase exports and position Uzbekistan as a regional pharmaceutical hub, supplying over 50 countries.
What role do you see Uzbekistan playing in regional and global pharmaceutical supply chains over the next decade, particularly within the CIS and neighbouring markets?
Over the next decade, Uzbekistan aims to become one of the leading pharmaceutical manufacturing and distribution hubs in the broader Central Asian and CIS region.
Due to its geographic location, Uzbekistan has strong logistical potential to serve neighbouring markets efficiently. At the same time, the Government is prioritizing export-oriented industrialization and localization policies to reduce dependency on imports while strengthening regional supply resilience.
We see Uzbekistan playing several important roles:
· a regional manufacturing hub for pharmaceuticals and biotechnology products;
· a platform for technology transfer and contract manufacturing;
· a logistics and export center connecting CIS, Central Asian, and nearby international markets;
· and increasingly, a regional center for pharmaceutical innovation and education.
As production capacity and regulatory harmonization continue to improve, Uzbekistan’s integration into global pharmaceutical supply chains is expected to deepen substantially.
With global pharmaceutical innovation accelerating and Uzbekistan investing heavily in infrastructure and partnerships, how do you envision the evolution of pharmaceutical R&D in Uzbekistan over the next 5–10 years, and what milestones would define success for the country in becoming an innovation-driven pharma hub?
Over the next 5–10 years, we expect Uzbekistan’s pharmaceutical sector to evolve from primarily manufacturing-focused activities toward a more innovation-driven ecosystem.
Key milestones for success would include:
· establishment of internationally recognized R&D centers;
· growth of biotechnology manufacturing capabilities;
· expansion of clinical research activities;
· development of locally generated intellectual property and innovative products;
· increased participation of Uzbek institutions in international scientific collaboration;
· and stronger integration into global pharmaceutical value chains.
We also expect greater collaboration between academia, industry, and government institutions. In the long term, our ambition is for Uzbekistan to become not only a production center, but also a recognized regional platform for pharmaceutical science, biotechnology, and healthcare innovation.
How is Uzbekistan aligning its regulatory framework (e.g., GMP, pharmacovigilance, digitalization) with international standards to support innovation and investor confidence?
Uzbekistan is undertaking significant reforms to align its pharmaceutical regulatory framework with international standards and best practices.
This includes strengthening GMP and GDP compliance systems, modernizing pharmacovigilance mechanisms, digitalizing regulatory procedures, and improving transparency and efficiency in product registration processes.
Particular attention is being paid to international cooperation and institutional capacity building, including engagement related to PIC/S alignment and inspector training. Uzbekistan is also working to enhance the quality management systems of its regulatory and inspection bodies to build greater international confidence.
Regulatory modernization is essential not only for investor confidence, but also for ensuring the safety, quality, and competitiveness of pharmaceutical products manufactured in Uzbekistan.
Following the recent presidential decree expanding the Agency’s mandate to include healthcare/medical sector, how will this broader responsibility reshape the Agency’s strategic priorities, and what new areas, such as medical technologies, healthcare infrastructure, or clinical services, will come into focus?
The recent presidential decree expanding the Agency’s responsibilities into the broader healthcare and medical sector marks an important strategic transformation.
This expanded mandate reflects the Government’s vision of creating a more integrated life sciences and healthcare ecosystem. In addition to pharmaceuticals, greater focus will now be placed on medical technologies, healthcare infrastructure development, biotechnology, clinical services, medical innovation, and advanced healthcare manufacturing.
The Agency’s role is therefore evolving from a sector-specific industrial body into a broader strategic institution supporting the development of healthcare, pharmaceuticals, biotechnology, and medical technologies in a coordinated manner.
This transformation is expected to create stronger synergies between healthcare delivery, industrial development, innovation, and investment attraction.
With this expanded mandate, will the Agency’s official name or institutional structure be revised, and how do you assess its long-term trajectory in terms of scale, influence, and role within Uzbekistan’s healthcare and life sciences ecosystem?
Following a recent Presidential Decree adopted a few weeks ago, the Agency has officially been renamed as the Medical and Pharmaceutical Industry Development Agency under the Ministry of Health of the Republic of Uzbekistan.
This institutional transformation reflects the Government’s broader strategic vision for the integrated development of both the pharmaceutical and medical sectors. In addition to continuing its work in pharmaceutical industry development, biotechnology, investment attraction, and localization, the Agency will now also take responsibility for supporting the development of the medical sector in Uzbekistan.
This expanded mandate will include greater focus on areas such as medical technologies, medical equipment manufacturing, healthcare infrastructure, clinical services, and broader healthcare innovation initiatives.
We believe this new structure will allow for stronger coordination between healthcare and industry, while creating additional opportunities for international partnerships, technology transfer, and investment across the wider life sciences ecosystem.
In the long term, the Agency is expected to play an increasingly important role in positioning Uzbekistan as a regional hub for pharmaceuticals, biotechnology, and medical technologies, while supporting the modernization and sustainable development of the country’s healthcare system.
|